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Background: Mercury is known to be neurotoxic, but its effects on the immune system are less well known. Mast
cells are involved in allergic reactions, but also in innate and acquired immunity, as well as in inflammation. Many
patients with Autism Spectrum Disorders (ASD) have “allergic” symptoms; moreover, the prevalence of ASD in
patients with mastocytosis, characterized by numerous hyperactive mast cells in most tissues, is 10-fold higher than
the general population suggesting mast cell involvement. We, therefore, investigated the effect of mercuric
chloride (HgCl2) on human mast cell activation.
Methods: Human leukemic cultured LAD2 mast cells and normal human umbilical cord blood-derived cultured
mast cells (hCBMCs) were stimulated by HgCl2 (0.1-10 μM) for either 10 min for beta-hexosaminidase release or
24 hr for measuring vascular endothelial growth factor (VEGF) and IL-6 release by ELISA.
Results: HgCl2 induced a 2-fold increase in b-hexosaminidase release, and also significant VEGF release at 0.1 and
1 μM (311 ± 32 pg/10
6 cells and 443 ± 143 pg/10
6 cells, respectively) from LAD2 mast cells compared to control
cells (227 ± 17 pg/10
6 cells, n = 5, p < 0.05). Addition of HgCl2 (0.1 μM) to the proinflammatory neuropeptide
substance P (SP, 0.1 μM) had synergestic action in inducing VEGF from LAD2 mast cells. HgCl2 also stimulated
significant VEGF release (360 ± 100 pg/10
6 cells at 1 μM, n = 5, p < 0.05) from hCBMCs compared to control cells
(182 ± 57 pg/10
6 cells), and IL-6 release (466 ± 57 pg/10
6 cells at 0.1 μM) compared to untreated cells (13 ± 25
pg/10
6 cells, n = 5, p < 0.05). Addition of HgCl2 (0.1 μM) to SP (5 μM) further increased IL-6 release.
Conclusions: HgCl2 stimulates VEGF and IL-6 release from human mast cells. This phenomenon could disrupt the
blood-brain-barrier and permit brain inflammation. As a result, the findings of the present study provide a
biological mechanism for how low levels of mercury may contribute to ASD pathogenesis.
Background
Heavy metals such as mercury result in neurological
injury that may lead to developmental defects, periph-
eral neuropathies, and enhanced neurodegenerative
changes [1]. Mercurials may be found in various drugs,
in bleaching creams, antiseptics, disinfectants, as preser-
vatives in cosmetics, tooth pastes, lens solutions, vac-
cines, contraceptives and immunotherapy solutions,
fungicides, herbicides and in dental fillings, as well as in
fish such as tuna due to water pollution [2]. Mercury
can cause immune, sensory, neurological, motor, and
behavioral dysfunction similar to those associated with
Autism Spectrum Disorders (ASD) [2]. The possible role
of mercury used as preservative in vaccines [2] has been
debated extensively, but most epidemiological studies do
not support a causal association between vaccines and
autism [3-7]. However, 87% of children included in the
US Vaccine Adverse Event Reporting System (VAERS)
had ASD [8]. Moreover, a paper based on computerized
medical records in the Vaccine Safety Data-link con-
cluded there was “significantly increased rate ratios for
ASD with mercury exposure from thiomerosal-contain-
ing vaccines” [9]. Mercury has been shown to induce
proliferation and cytokine production from T lympho-
cytes [10]. Mercuric chloride (HgCl2)i nn o n t o x i cd o s e s
induces the release of histamine and cytokines, such as
IL-4 and tumor necrosis factor-alpha (TNF-a), from a
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derived cultured mast cells [11]. HgCl2 (100 μM) also
enhances immunoglobulin E-mediated mediator release
from human basophils [12], and histamine release from
a rat basophil cell line (RBL-2H3) [13].
We, therefore, investigated whether HgCl2 could stimu-
late human mast cells, an action that could be enhanced
in subjects who already have an atopic background.
Methods
HgCl2 was obtained from Fluka Chemical Corp. (Mil-
waukee, WI) and was diluted in Dulbecco’sp h o s p h a t e
buffered saline (DPBS, GIBCO, Grand Island, NY) on
the day of the experiments.
Human mast cell culture
LAD2 and human umbilical cord blood-derived cultured
mast cells (hCBMCs) were cultured as previously
described [14,15]. Umbilical cord blood was collected as
approved by the Tufts Medical Center’s( B o s t o n ,M A )
Investigation Review Board in tubes containing 10 U/ml
heparin, blood was diluted 1:2 with DPBS, GIBCO) con-
taining 2 mM ethylenediaminetetraacetic acid (Sigma,
St. Louis, MO). Non-phagocytic mononuclear cells were
separated by density-gradient centrifugation using Lym-
phocyte Separation Medium (LSM) from Organon
Teknika Corp. (Durham, NC). The isolation of hemato-
poietic stem and progenitor cells (CD34
+) was performed
by positive selection of AC133-expressing cells by mag-
netic-associated cell sorting (MACS) using an AC133 cell
isolation kit (Milltenyi Biotec, Auburn, CA) as reported
previously [15,16]. CD34
+ cells were suspended in AIM-V
Medium (GIBCO BRL), supplemented with 100 to 200
ng/ml recombinant human stem cell factor (rhSCF,
Amgen, Thousand Oaks, CA), 50 ng/ml IL-6 (Millipore,
Temecula, CA) and cultured for 12 to 16 weeks. During
this culture period, the cells were washed with DPBS every
week and resuspended using fresh culture medium. The
purity of hCBMCs was evaluated by immunocytochemical
staining for tryptase as previously described [15]. Mast cell
viability was determined by Trypan blue (0.3%) exclusion
method. LAD2 cells cultured over 10 days and hCBMCs
cultured over 12 weeks were used for the experiments.
Histamine assay
LAD2 or hCBMCs cells were washed with DPBS and
mast cell media, once in each. Cell suspensions (5 × 10
4
cells per tube, 500 μl/sample) were preincubated with
either the neuropeptide substance P (SP, 0.1-2 μM) or
anti-IgE (10 μg/ml) as positive controls, or HgCl2 (1-10
μM) for 30 min. After the reaction, the cells were cen-
trifuged and the supernatant fluid was collected.
Histamine levels were assayed using EIA histamine kit
(# IM2015; Immunotech, Beckman Coulter Company,
France) as per the directions. Histamine release was cal-
culated as percent of total.
b-Hexosaminidase assay
b-Hexosaminidase release, as an index of mast cell
degranulation, was assayed using a fluorometric assay as
previously reported [17]. Briefly, b-hexosaminidase activ-
ity in the supernatant fluid and cell lysates (LAD2 cells,
0.5 × 10
5/tube, were lysed with 1% Triton X-100 to
measure residual cell-associated b-hexosaminidase) were
incubated with substrate solution (p-nitrophenyl-N-
acetyl-b-D-glucosaminide from Sigma, St Louis, MO) in
0.1 M citrate buffer (pH 4.5) for 60 min at 37°C. The
reaction was terminated by the addition 0.2 M NaOH/
0.2 M glycine. Absorbance was read at 405 nm in an
enzyme-linked immunosorbent assay reader, and the
results are expressed as the percentage of b-hexosamini-
dase activity released over the total.
Cytokine assay
LAD2 cells or hCBMCs were washed with DPBS, sterile
Tyrode’s buffer, and plain culture medium, once in
each, and were suspended in complete culture medium
without IL-6 (for hCBMCs). The LAD 2 cells or
hCBMCs (2 × 10
5 cells/well/200 μl) were plated in 96-
well, flat-bottom Falcon cell culture plates (Becton Dick-
inson) and were pre-incubated for 15 min at 37°C in a
5% CO2 incubator. The cells were then incubated with
either neuropeptide SP (0.1-2 μM) or HgCl2 (1-10 μM)
for 24 hours at 37°C. Control cells were treated with
equal volumes of only the respective culture medium.
After the reaction time, plates were centrifuged and the
supernatant medium was gently collected from the wells
and stored at -80°C until the cytokines were measured
by enzyme-linked immunosorbent assay (ELISA) using a
commercial kit (Quantikine, R&D Systems, Minneapolis,
MN), as reported previously [18]. The minimum detect-
able levels of VEGF and IL-6 were 5 pg/ml. Cell viability
was assessed at 1 hour and at 24 hours using the Try-
pan blue exclusion method.
Statistical analysis
All conditions were performed in triplicate, and all
experiments were repeated five times (n = 5). Results
are presented as mean ± SD. Data from two conditions,
such as stimulated and control samples, were compared
using the Unpaired 2-tailed Student’s t-test. Significance
of comparisons is denoted by p < 0.05.
Results
Effects of HgCl2 on mast cell viability
LAD2 mast cells and hCBMCs were incubated with
HgCl2 for 1 hour or for 24 hours in their respective
media, and cell viability was assessed by Trypan blue
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culture medium only slightly (10%), only at concentra-
tion of 10 μM, and only after 24 hours of incubation
( n=3 ,F i g .1 A ) .H g C l 2 reduced viability of hCBMCs by
25% at concentration of 10 μM after 24 hours of incuba-
tion (n = 5; Fig. 1B).
Effects of HgCl2 on LAD2 mast cell histamine release
We first tried to study the effect of HgCl2 on mast cell
histamine release. We assayed histamine release from
LAD2 mast cells and hCBMCs after incubation with
HgCl2 (1-10 μM) for another 30 min at 37°C in Tyrode’s
buffer. Addition of HgCl2 for 30 min induced statisti-
cally significant histamine release from hCBMCs, com-
pared to control cells, at HgCl2 concentrations of 0.1
and 1 μM. However, as the results were inconsistent
due to interference of HgCl2 with the histamine assay,
we do not present them. Instead, we investigated the
effect of HgCl2 on the release of b-hexosaminidase,
another secretory granule marker that is released in par-
allel with histamine. Only 10 μMH g C l 2 was able to
i n d u c ea2 - f o l di n c r e a s ei nb-hexosaminidase release
(Fig. 2A, n = 5, p < 0.05).
Effects of HgCl2 on LAD2 mast cell VEGF release
We then investigated whether HgCl2 could stimulate
release of proinflammatory mediators from mast cells.
LAD2 mast cells released significantly more VEGF at
HgCl2 concentrations of 0.1 and 1 μM (311 ± 32 pg/10
6
cells and 443 ± 143 pg/10
6 cells, respectively, compared
to 227 ± 17 pg/10
6 cells for control cells, p < 0.05, Fig.
2B). HgCl2 (0.1 μM) had a statistically significant syner-
gistic effect on LAD2 mast cell VEGF release (693 ± 102
pg/106 cells) when added with SP (0.1 μM) (Fig. 2B).
Combinations of higher concentrations of HgCl2 and SP
did not induce any additional VEGF release.
Effects of HgCl2 on hCBMC VEGF and IL-6 release
HgCl2 (1 μM) also induced release of significantly more
VEGF (182 ± 57 pg/10
6 cells) from hCBMCs (n = 5, p <
0.05) compared to control cells (360 ± 100 pg/10
6 cells)
(Fig. 3A).
Figure 1 Effects of HgCl2 on (A) LAD2 mast cells and (B) hCBMCs viability assayed by supravital staining with Trypan blue. LAD2 mast
cells and hCBMCs were incubated with HgCl2 one hour or 24 hours at 37°C and the viability was assayed (n = 3).
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fore, investigated the effect of HgCl2 on IL-6 release
from hCBMCs. HgCl2 (0.1 and 1 μM) significantly
induced IL-6 release (466 ± 57 pg/10
6 cells and 204 ±
47 pg/10
6 cells, respectively) compared to untreated
control cells (13 ± 25 pg/10
6 cells, n = 5, Fig. 3B). SP (5
μM), used as a positive control, also significantly
increased IL-6 release (609 ± 57 pg/10
6 cells) from
hCBMCs. Addition of HgCl2 (0.1) with SP (5 μM)




This is the first report to our knowledge showing that
inorganic mercury in concentrations as low as 0.1 μM
can induce VEGF and IL-6 release from human cultured
mast cells. We also report for the first time that mer-
cury has a significant synergistic effect with SP (0.1 μM)
on VEGF release; this amount of VEGF release is higher
than what has previously been reported for hCBMCs
[19]. One paper has reported that HgCl2 can induce
release of histamine from primary lung and human leu-
kemic mast cells (HMC-1 cells), but only at toxic levels
of 0.33 mM [20]. Here we show that HgCl2 induces b-
hexosaminidase release, but only at a concentration of
10 μM. Mercury (10 μM) has previously been shown to
induce release of b-hexosaminidase, IL-4 and TNF-a
f r o mam u r i n em a s tc e l ll i n ea n df r o mm o u s eb o n e
marrow-derived cultured mast cells; the secretion of
Figure 2 Effects of HgCl2 on (A) b-hexosaminidase and (B)
VEGF release from LAD2 mast cells. LAD2 mast cells were
incubated with HgCl2 and/or SP as indicated for 10 min for b-
hexosaminidase and 24 hours for VEGF release at 37°C. The cells
were then centrifuged and the supernatant fluid was collected.
VEGF release was assayed by ELISA, while b-hexosaminidase release
was assayed spectrophotometrically (n = 5, *p < 0.05).
Figure 3 Effects of HgCl2 on VEGF release from hCBMCs.M a s t
cells were incubated with HgCl2 and/or SP as indicated for 24 hours
at 37°C. The cells were then centrifuged and the supernatant fluid
was collected. VEGF (A) and IL-6 (B) release from hCBMCs was
assayed by ELISA (n = 5, *p < 0.05).
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follows FcepsilonRI-induced mast cell activation [11]. In
contrast, HgCl2 does not have an effect on its own on
release of histamine and IL-4 from human basophil, but
only enhances allergic release at concentrations of 1 and
10 μM [12]. This is also true for IL-4 release from rat
mast cells [21]. Clinical symptoms of mercury poisoning
may be expected at blood levels of 1 μM [12]. However,
brain mast cells may react to lower mercury concentra-
tions, especially in vulnerable patient subpopulations.
Mast cells, by virtue of their location in the skin,
respiratory tract, and gastrointestinal system are poten-
tial targets for environmental agents with immunotoxic
effects [22]. Mast cells are critical not only for allergic
reactions, but also important in both innate and
acquired immunity [23], as well as in inflammation [24].
In view of the fact that a subgroup of ASD patients
have allergy symptoms that do not appear to be trig-
gered by IgE, it is noteworthy that mast cells can be sti-
mulated by non-allergic triggers originating in the gut
or the brain [24], especially neuropeptides such as SP
[25] and neurotensin (NT) [26]. Once activated, mast
cells secrete numerous vasoactive, neurosensitizing and
proinflammatory molecules that are relevant to ASD;
these include histamine, proteases, VEGF, prostaglandin
D2, as well as cytokines such as IL-6 [24]. In particular,
mast cells can secrete VEGF [27,28], an isoform of
which is vasodilatory [29] and is over expressed in
delayed hypersensitivity reactions [30]. In fact, mast cells
can release VEGF [31], IL-6 [32] and other mediators
“selectively” without degranulation [33]. Such mediators
could disrupt the gut-blood and blood-brain barriers
(BBB) permitting brain inflammation [34]. It is impor-
tant to note that mercury can cross the BBB through a
transport mechanism that can lead to significant brain
concentrations, and that can persist for prolonged peri-
ods of time [2,35]. Activated brain mast cells can disrupt
the BBB [36,37] and further increase brain mercury
levels.
The mechanisms of heavy metal neurotoxicity are not
fully understood. Mercury increases cytosolic calcium
levels in PC12 cells [38], and thimerosal does so in thy-
mus lymphocytes [39]. Mercury may also increase cellu-
l a ro x i d a t i v es t r e s ss i n c en e u r o n sa r eh i g h l ys u s c e p t i b l e
to reactive oxygen species (ROS) and neuronal mito-
chondria are especially vulnerable to oxidative damage
[40]. In fact, the primary dietary source of neurotoxic
mercury compounds is via the ingestion of methylmer-
cury from fish, which has been previously linked to
neurological damage [41].
Mercury’s activation of mast cell inflammatory media-
tor release may enhance allergic reactions in atopic indi-
viduals and exacerbate IgE-dependent diseases [12].
Allergic symptomatology is often present in ASD patients
[34], and a survey of children with ASD in Italy reported
that the strongest association was with a history of aller-
gies [42]. Moreover, a recent study reported increased
atopic diseases, as well as elevated serum IgE and eosino-
phils in Asperger patients [43]. In a National Survey of
Children’s Health, parents of autistic children reported
symptoms of allergies more often than other children,
with food allergies showing the greatest difference [44]. A
case series study also reported higher rate of food aller-
gies in ASD children [45]. In one study, 30% of autistic
children (n = 30) had a history of atopy as compared to
2.5% of age-matched “neurologic controls” (n = 30), but
there was no difference in serum IgE or in skin prick
tests to 12 common antigens [46], implicating triggers
other than IgE. In another study, ASD patients did not
have increased incidence of allergic asthma or allergic
dermatitis [42], but this study included only ASD patients
that were positive to RAST/skin testing. Finally, a preli-
minary report indicated that the prevalence of ASD may
be 10-fold higher [47] than the general population (1/100
children) in mastocytosis patients [48], characterized by
increased number of hyperactive mast cells in many
tissues, with symptoms that include allergies, food intol-
erances and “brain fog” [49,50].
Some epidemiological studies have failed to find a sig-
nificant relationship between mercury exposure from
vaccines and autism [3-7]. Nevertheless, 87% of children
included in the US Vaccine Adverse Event Reporting
System (VAERS) have ASD [8]. Moreover, a paper
based on computerized medical records in the Vaccine
Safety Datalink concluded there was “significantly
increased rate ratios for ASD with mercury exposure
from Thimerosal-containing vaccines” [9]. Also, there
are a series of epidemiological studies conducted in the
USA that have found significant associations between
environmental sources of mercury exposure and ASDs
[51]. In addition, patients with severe ASD have
evidence of significantly increased urinary porphyrins
consistent with mercury intoxication [52-55]. Mercury
toxicity may also affect critical methylation pathways in
vulnerable cells [56].
ASD are a group of pervasive developmental disorders
that include autistic disorder, Asperger’sd i s o r d e r ,a n d
atypical autism - also known as pervasive developmental
disorder-not otherwise specified (PDD-NOS). These are
neurodevelopmental disorders diagnosed in early child-
hood [57]. They are characterized by various degrees of
dysfunctional communication and social skills, repetitive
and stereotypic behaviors, as well as attention, cognitive,
learning and sensory defects [57,58]. ASD cases have
increased more than 10-fold during the last decade to a
prevalence of 1/100 children [44,57,59]. However, there
is no known distinct pathogenesis, there are no biomar-
kers, and there is no effective treatment [60].
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chemical susceptibility and epigenetic exposure to envir-
onmental factors, including reduced ability to excrete
mercury and/or exposure to mercury at critical develop-
mental periods [2,56]. A number of papers have sug-
gested that ASD may be associated with immune
dysfunction [61], while a recent review made the case
that ASD may be a neuroimmune disorder involving
mast cell activation [34].
Conclusions
The results of the present study support the biological
plausibility of how mercury could contribute to ASD
pathogenesis by inducing VEGF and IL-6 release from
mast cells, and as a result disrupt the BBB and thus per-
mit brain inflammation. Further studies should investi-
gate the effect of mercury and thimerosal alone or
together with allergic and non-immune triggers.
Abbreviations
ASD: Autism Spectrum Disorders; (DPBS): Dulbecco’s phosphate buffered
saline; hCBMCs: human umbilical cord blood-derived cultured mast cells;
ELISA: enzyme-linked immunosorbent assay; HgCl2: mercury chloride; PDD-
NOS: pervasive developmental disorder-not otherwise specified; (NT):
neurotensin; (SP): Substance P; rhSCF: recombinant human stem cell factor;
VAERS: Vaccine Adverse Event Reporting System; VEGF: vascular endothelial
growth factor.
Acknowledgements
This work was funded in part by the Safe Minds (Huntington Beach, CA) and
the Defeat Autism Now Coalition (San Diego, CA), as well as Theta
Biomedical Consulting and Development Co., Inc. (Brookline, MA). Christos
Damianos Kalogeromitros participated in some aspects of this work as part
of his IB project at Athens College, Greece.
Author details
1Molecular Immunopharmacology and Drug Discovery Laboratory,
Department of Pharmacology and Experimental Therapeutics, Tufts
University School of Medicine and Tufts Medical Center, Boston, MA 02111,
USA.
2Department of Obstetrics & Gynecology, Maternal-Fetal Medicine, Tufts
University School of Medicine and Tufts Medical Center, Boston, MA 02111,
USA.
3Department of Biochemistry, Tufts University School of Medicine,
Boston, MA 02111, USA.
4Department of Internal Medicine, Tufts University
School of Medicine and Tufts Medical Center, Boston, MA 02111, USA.
5Department of Psychiatry, Tufts University School of Medicine and Tufts
Medical Center, Boston, MA 02111, USA.
Authors’ contributions
This study is based on an original idea of TCT. TCT and DK wrote the
manuscript. DK and SA carried out the cytokine, b-hexosaminidase and
histamine assays. JH, AM, BZ carried out the viability assays and some
mediator assays. EP provided umbilical cord blood. All authors have read
and approved the manuscript.
Competing interests
TCT is on the Scientifc Advisory Board of The Mastocytosis Society. TCT is
the inventor of US patents No. 6,624,148; 6,689,748; 6,984,667 and EPO
1365777, which cover methods and compositions of mast cell blockers in
neuroinflammatory conditions, as well as US patent application No.12/
534,571 for diagnosis and treatment of ASD.
Received: 3 December 2009 Accepted: 11 March 2010
Published: 11 March 2010
References
1. Monroe RK, Halvorsen SW: Environmental toxicants inhibit neuronal Jak
tyrosine kinase by mitochondrial disruption. NeuroToxicol 2009,
30:589-598.
2. Geier DA, King PG, Sykes LK, Geier MR: A comprehensive review of
mercury provoked autism. Indian J Med Res 2008, 128:383-411.
3. Stehr-Green P, Tull P, Stellfeld M, Mortenson PB, Simpson D: Autism and
thimerosal-containing vaccines: lack of consistent evidence for an
association. Am J Prev Med 2003, 25:101-106.
4. D’Souza Y, Fombonne E, Ward BJ: No evidence of persisting measles virus
in peripheral blood mononuclear cells from children with autism
spectrum disorder. Pediatrics 2006, 118:1664-1675.
5. DeStefano F: Vaccines and autism: evidence does not support a causal
association. Clin Pharmacol Ther 2007, 82:756-759.
6. Baker JP: Mercury, vaccines, and autism: One controversy, three histories.
Am J Public Health 2008, 98:244-253.
7. Fombonne E: Thimerosal disappears but autism remains. Arch Gen
Psychiatry 2008, 65:15-16.
8. Woo EJ, Ball R, Landa R, Zimmerman AW, Braun MM: Developmental
regression and autism reported to the Vaccine Adverse Event Reporting
System. Autism 2007, 11:301-310.
9. Young HA, Geier DA, Geier MR: Thimerosal exposure in infants and
neurodevelopmental disorders: an assessment of computerized medical
records in the Vaccine Safety Datalink. J Neurol Sci 2008, 271:110-118.
10. Jiang Y, Moller G: In vitro effects of HgCl2 on murine lymphocytes. I.
Preferable activation of CD4+ T cells in a responder strain. J Immunol
1995, 154:3138-3146.
11. Dastych J, Walczak-Drzewiecka A, Wyczolkowska J, Metcalfe DD: Murine
mast cells exposed to mercuric chloride release granule-associated
N-acetyl-beta-D-hexosaminidase and secrete IL-4 and TNF-alpha. J Allergy
Clin Immunol 1999, 103:1108-1114.
12. Strenzke N, Grabbe J, Plath KE, Rohwer J, Wolff HH, Gibbs BF: Mercuric
chloride enhances immunoglobulin E-dependent mediator release from
human basophils. Toxicol Appl Pharmacol 2001, 174:257-263.
13. Suzuki Y, Yoshimaru T, Yamashita K, Matsui T, Yamaki M, Shimizu K:
Exposure of RBL-2H3 mast cells to Ag(+) induces cell degranulation and
mediator release. Biochem Biophys Res Commun 2001, 283:707-714.
14. Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, et al:
Characterization of novel stem cell factor responsive human mast cell
lines LAD 1 and 2 established from a patient with mast cell sarcoma/
leukemia; activation following aggregation of FcepsilonRI or FcgammaRI.
Leuk Res 2003, 27:677-682.
15. Kempuraj D, Saito H, Kaneko A, Fukagawa K, Nakayama M, Toru H, et al:
Characterization of mast cell-committed progenitors present in human
umbilical cord blood. Blood 1999, 93:3338-3346.
16. Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-
Grzybowska K, Madhappan B, et al: Corticotropin-releasing hormone and
its structurally related urocortin are synthesized and secreted by human
mast cells. Endocrinology 2004, 145:43-48.
17. Puri N, Roche PA: Mast cells possess distinct secretory granule subsets
whose exocytosis is regulated by different SNARE isoforms. Proc Natl
Acad Sci USA 2008, 105:2580-2585.
18. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J,
Papadopoulou N, et al: Flavonols inhibit proinflammatory mediator
release, intracellular calcium ion levels and protein kinase C theta
phosphorylation in human mast cells. Br J Pharmacol 2005, 145:934-944.
19. Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W,
et al: Luteolin inhibits myelin basic protein-induced human mast cell
activation and mast cell dependent stimulation of Jurkat T cells. Br J
Pharmacol 2008, 155:1076-1084.
20. Schedle A, Samorapoompichit P, Fureder W, Rausch-Fan XH, Franz A,
Sperr WR, et al: Metal ion-induced toxic histamine release from human
basophils and mast cells. J Biomed Mater Res 1998, 39:560-567.
21. Wu Z, Pearson A, Oliveira D: Characterization of cis-regulatory elements
conferring mercury-induced interleukin-4 gene expression in rat mast
cells: a role for signal transducer and activator of transcription 6 and
TATA box binding sites. Immunology 2009, 127:530-538.
22. Paus R, Theoharides TC, Arck PC: Neuroimmunoendocrine circuitry of the
‘brain-skin connection’. Trends Immunol 2006, 27:32-39.
Kempuraj et al. Journal of Neuroinflammation 2010, 7:20
http://www.jneuroinflammation.com/content/7/1/20
Page 6 of 723. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM,
Tsai M: Mast cells as “tunable” effector and immunoregulatory cells:
recent advances. Annu Rev Immunol 2005, 23:749-786.
24. Theoharides TC, Kalogeromitros D: The critical role of mast cell in allergy
and inflammation. Ann NY Acad Sci 2006, 1088:78-99.
25. Janiszewski J, Bienenstock J, Blennerhassett MG: Picomolar doses of
substance P trigger electrical responses in mast cells without
degranulation. Am J Physiol 1994, 267:C138-C145.
26. Carraway R, Cochrane DE, Lansman JB, Leeman SE, Paterson BM, Welch HJ:
Neurotensin stimulates exocytotic histamine secretion from rat mast
cells and elevates plasma histamine levels. J Physiol 1982, 323:403-414.
27. Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP, et al:
Mast cells can secrete vascular permeability factor/vascular endothelial
cell growth factor and exhibit enhanced release after immunoglobulin
E-dependent upregulation of Fcε receptor I expression. J Exp Med 1998,
188:1135-1145.
28. Grutzkau A, Kruger-Krasagakes S, Baumeister H, Schwarz C, Kogel H,
Welker P, et al: Synthesis, storage and release of vascular endothelial
growth factor/vascular permeability factor (VEGF/VPF) by human mast
cells: Implications for the biological significance of VEGF206. Mol Biol Cell
1998, 9:875-884.
29. Laham RJ, Li J, Tofukuji M, Post M, Simons M, Sellke FW: Spatial
heterogeneity in VEGF-induced vasodilation: VEGF dilates microvessels
but not epicardial and systemic arteries and veins. Ann Vasc Surg 2003,
17:245-252.
30. Brown LF, Olbricht SM, Berse B, Jackman RW, Matsueda G, Tognazzi KA,
et al: Overexpression of vascular permeability factor (VPF/VEGF) and its
endothelial cell receptors in delayed hypersensitivity skin reactions. J
Immunol 1995, 154:2801-2807.
31. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL,
et al: Human mast cells express corticotropin-releasing hormone (CRH)
receptors and CRH leads to selective secretion of vascular endothelial
growth factor. J Immunol 2005, 174:7665-7675.
32. Kandere-Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S,
Boucher W, et al: IL-1 induces vesicular secretion of IL-6 without
degranulation from human mast cells. J Immunol 2003, 171:4830-4836.
33. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D:
Differential release of mast cell mediators and the pathogenesis of
inflammation. Immunol Rev 2007, 217:65-78.
34. Theoharides TC, Kempuraj D, Redwood L: Autism: an emerging
‘neuroimmune disorder’ in search of therapy. Exp Opinion on
Pharmacotherapy 2009, 10:2127-2143.
35. Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson T:
Comparison of blood and brain mercury levels in infant monkeys
exposed to methylmercury or vaccines containing thimerosal. Environ
Health Perspect 2005, 113:1015-1021.
36. Esposito P, Gheorghe D, Kandere K, Pang X, Conally R, Jacobson S, et al:
Acute stress increases permeability of the blood-brain-barrier through
activation of brain mast cells. Brain Res 2001, 888:117-127.
37. Esposito P, Chandler N, Kandere-Grzybowska K, Basu S, Jacobson S,
Connolly R, et al: Corticotropin-releasing hormone (CRH) and brain mast
cells regulate blood-brain-barrier permeability induced by acute stress. J
Pharmacol Exp Ther 2002, 303:1061-1066.
38. Rossi AD, Larsson O, Manzo L, Orrenius S, Vahter M, Berggren PO, et al:
Modifications of Ca2+ signaling by inorganic mercury in PC12 cells.
FASEB J 1993, 7:1507-1514.
39. Elferink JG: Thimerosal: a versatile sulfhydryl reagent, calcium mobilizer,
and cell function-modulating agent. Gen Pharmacol 1999, 33:1-6.
40. Kidd PM: Neurodegeneration from mitochondrial insufficiency: nutrients,
stem cells, growth factors, and prospects for brain rebuilding using
integrative management. Altern Med Rev 2005, 10:268-293.
41. Harris HH, Pickering IJ, George GN: The chemical form of mercury in fish.
Science 2003, 301:1203.
42. Persico AM, Sacco R, Curatolo P, Manzi B, Lenti C, Saccani M, et al: Isolation
of principal components in autistic disorder symptomatology and their
association with biological endophenotypes. Proc Society for Neuroscience,
Washington DC 2008, Abstract #446.20.
43. Magalhaes ES, Pinto-Mariz F, Bastos-Pinto S, Pontes AT, Prado EA,
Deazevedo LC: Immune allergic response in Asperger syndrome. J
Neuroimmunol 2009, 1-2:108-112.
44. Gurney JG, McPheeters ML, Davis MM: Parental report of health
conditions and health care use among children with and without
autism: National Survey of Children’s Health. Arch Pediatr Adolesc Med
2006, 160:825-830.
45. Jyonouchi H, Geng L, Cushing-Ruby A, Quraishi H: Impact of innate
immunity in a subset of children with autism spectrum disorders: a case
control study. J Neuroinflammation 2008, 5:52.
46. Bakkaloglu B, Anlar B, Anlar FY, Oktem F, Pehlivanturk B, Unal F, et al:
Atopic features in early childhood autism. Eur J Paediatr Neurol 2008,
12:476-479.
47. Theoharides TC: Autism spectrum disorders and mastocytosis. Int J
Immunopathol Pharmacol 2009, 22:859-865.
48. Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM,
et al: Prevalence of parent-reported diagnosis of autism spectrum
disorder among children in the US, 2007. Pediatrics 2009, 5:1395-1403.
49. Castells M: Mast cell mediators in allergic inflammation and
mastocytosis. Immunol Allergy Clin North Am 2006, 26:465-485.
50. Akin C, Valent P, Escribano L: Urticaria pigmentosa and mastocytosis: the
role of immunophenotyping in diagnosis and determining response to
treatment. Curr Allergy Asthma Rep 2006, 6:282-288.
51. Palmer RF, Blanchard S, Stein Z, Mandell D, Miller C: Environmental
mercury release, special education rates, and autism disorder: an
ecological study of Texas. Health Place 2006, 12:203-209.
52. Geier DA, Kern JK, Garver CR, Adams JB, Audhya T, Nataf R, et al:
Biomarkers of environmental toxicity and susceptibility in autism. J
Neurol Sci 2008, 280:101-108.
53. Geier DA, Geier MR: A prospective study of mercury toxicity biomarkers
in autistic spectrum disorders. J Toxicol Environ Health A 2007,
70:1723-1730.
54. Adams JB, Romdalvik J, Ramanujam VM, Legator MS: Mercury, lead, and
zinc in baby teeth of children with autism versus controls. J Toxicol
Environ Health A 2007, 70:1046-1051.
55. Desoto MC, Hitlan RT: Blood levels of mercury are related to diagnosis of
autism: a reanalysis of an important data set. J Child Neurol 2007,
22:1308-1311.
56. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M: How
environmental and genetic factors combine to cause autism: A redox/
methylation hypothesis. NeuroToxicol 2008, 29:190-201.
57. Fombonne E: Epidemiology of pervasive developmental disorders. Pediatr
Res 2009, 65:591-598.
58. Johnson CP, Myers SM: Identification and evaluation of children with
autism spectrum disorders. Pediatrics 2007, 120:1183-1215.
59. Theoharides TC, Angelidou A, Alysandratos K-A: Neonatal mast cell
activation and autism. Brain, Behavior, Immunity 2010.
60. Theoharides TC, Doyle R, Francis K, Conti P, Kalogeromitros D: Novel
therapeutic targets for autism. Trends Pharmacol Sci 2008, 29:375-382.
61. Ashwood P, Wills S, Water Van de J: The immune response in autism: a
new frontier for autism research. J Leukoc Biol 2006, 80:1-15.
doi:10.1186/1742-2094-7-20
Cite this article as: Kempuraj et al.: Mercury induces inflammatory
mediator release from human mast cells. Journal of Neuroinflammation
2010 7:20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kempuraj et al. Journal of Neuroinflammation 2010, 7:20
http://www.jneuroinflammation.com/content/7/1/20
Page 7 of 7